此前期招股說明書的信息並不完整，可能會發生變更。已在證券交易委員會備案了與這些證券有關的註冊聲明，並已生效。此前期招股說明書和隨附的招股說明書並不構成對這些證券的出售要約，我們也不會在任何不允許該出售的司法轄區內徵集對這些證券的購買要約。

根據424（b）（5）規則提交

註冊編號333-279857

須完成，日期爲2024年10月31日 

初步招股說明書補充

(截止日期爲2024年6月12日的招股說明書) 

股份

普通股

我們正在提供我們的普通股股份，每股面值爲0.01美元。

我們的普通股在納斯達克資本市場上市，或者稱爲「納斯達克」，股票代碼爲「ASPI」。2024年10月30日，我們的普通股在納斯達克的最後報價爲每股6.90美元。

投資我們的證券涉及高度風險。請參閱本招股說明書補充的第S-6頁上以及我們在證券交易委員會提交的備妥文件，這些文件已被引用到本招股說明書補充及其附屬招股說明書中，以了解在購買我們的普通股之前您應考慮的因素。

證券和交易委員會以及任何州證券委員會均未批准或否決了這些證券，也未核實或審查過本招股說明書補充或隨附招股說明書的充分性或準確性。任何相反陳述均構成犯罪行爲。

________________________________________

承銷商還有權選擇在本招股說明書補充稿件日期後30天內按照上述相同條款和條件購買額外股票。

承銷商預計將於2024年11月左右將股份交付給購買者。

Canaccord Genuity

2024年11月

目錄

招股書補充

招股說明書

關於此招股說明書補充的說明

本招股說明書補充和隨附招股說明書涉及我們普通股的發行。在購買我們正在提供的任何股票之前，我們建議您仔細閱讀本招股說明書補充、隨附的招股說明書、我們授權用於與本次發行相關的任何自由書面招股說明書，以及根據本招股說明書中「更多信息查詢處」和「引用特定信息的納入」標題所描述的參考信息。這些文件包含您在做出投資決定時應考慮的重要信息。

本招股說明書補充材料以及隨附的招股說明書是Form S-3（文件號333-279857）上一份「架子」註冊聲明的一部分，該註冊聲明於2024年6月12日被證券交易委員會（或「SEC」）宣佈生效。本文件包括兩部分。第一部分是本招股說明書補充材料，描述了本次發行的具體條款，並補充、更新了隨附招股說明書中包含的信息，以及已被引用至本招股說明書補充材料和隨附招股說明書中的文件。第二部分，即隨附招股說明書，提供更一般性的信息，部分信息可能與本次發行無關。通常情況下，我們提到本招股說明書時，指的是由本招股說明書補充材料和隨附招股說明書組成的聯合文件。在本招股說明書補充材料中，根據法律規定，我們使用「引用文件」中的信息。這意味着我們可以通過引用這些文件向您披露重要信息。被引用的信息被視爲本招股說明書補充材料和隨附招股說明書的一部分，並應當同樣仔細閱讀。當我們未來向SEC提交文件以更新已被引入的文件中的信息時，本招股說明書補充材料中包含或被引入的信息將被視爲自動更新和取代。換句話說，在本招股說明書補充材料中包含的信息與隨附招股說明書中的信息或被引入本招股說明書補充材料中的信息之間存在衝突或不一致情況時，您應當依賴於後者文件中的信息。

我們及承銷商未授權任何人提供除本招股說明書、隨附招股說明書或我們授權用於本次發行的任何自由書面招股說明書中所含或併入的信息之外的任何信息。我們和承銷商不對其他人可能提供給您的任何信息的可靠性承擔責任，也無法保證其可靠性。我們和承銷商不在任何未授權進行發行或在該發行或邀約的人未取得資格或向任何人邀約或承諾在任何未獲授權的司法管轄區進行買賣我們證券。在美國以外的人士持有本招股說明書和隨附招股說明書，必須了解並遵守與普通股發行和在美國以外分發本招股說明書和隨附招股說明書相關的任何限制。

您應該假設本招股說明書補充、隨附的招股說明書、通過引用納入本招股說明書補充和隨附的文件以及我們授權用於本次發行的任何自由書面說明書中的信息，僅截至這些文件的各自日期時是準確的。我們的業務、財務狀況、經營業績和前景可能自那些日期以來發生了變化。

除非上下文另有說明，本招股說明書中對「我們」、「我們的」和「我們」的引用指的是asp isotopes公司及其整體的合併子公司。

風險因素

投資於我們普通股的股份涉及高度風險。 在您決定投資我們普通股的股份之前，您應該仔細考慮下文中所描述的風險和不確定性，以及我們截至2023年12月31日的年度報告10-k中所述的，由我們隨後的SEC提交的修訂或補充報告中所涵蓋的，被引用並包含於本附錄和隨附之說明書中的所有其他信息。 我們目前不知道的風險和不確定性，或者我們目前認為不重要的風險和不確定性，也可能對我們的業務，財務狀況，營運業績和前景產生實質影響。 如果發生這些風險中的任何一種，我們的業務，前景，營運結果和財務狀況可能會受到重大損害。 在這種情況下，我們普通股的交易價格可能會下跌，您可能會失去您的全部或部分投資。

與我們的普通股、本次發行和其他事項相關的風險

我們普通股的交易價格一直都很波動，而且可能會繼續波動，對於各種因素可能會出現寬幅波動的反應，其中一些因素是我們無法控制的。

一般股市和我們普通股的市場經歷了極端的波動，這種波動經常與特定公司的營運表現無關。例如，自2022年11月首次公開募股至2024年10月30日我們普通股的最後報價，我們普通股的市場價格從9.23美元的高點下跌至0.32美元的低點。由於這種波動，您可能無法以公開發行價格或更高價賣出您的普通股，您可能會損失部分或全部投資。

如果證券分析師不對我們的業務發表研究或報告，或者他們對我們的股票發表負面評價，我們的股票價格可能下跌。

我們普通股的交易市場在一定程度上將依賴行業板塊或金融分析師針對我們或我們業務所發布的研究和報告。無法保證現有的分析師將繼續關注我們，或新的分析師將開始關注我們。也無法保證任何覆蓋我們的分析師將提供正面報導。缺乏研究報導或不利報導可能會對我們的普通股市價產生負面影響。此外，如果覆蓋我們業務的一名或多名分析師降級他們對我們的股票或我們行業其他公司股票的評估，我們股票的價格可能會下跌。

如果您在此次發行中購買普通股，您的投資將立即受到稀釋。

這次發行的普通股價格遠高於調整後每股普通股的淨有形價值。因此，如果您在本次發行中購買我們的普通股，您將以每股價格購買，該價格大大超過本次發行後我們的調整後每股淨有形價值。根據每股$的公開發行價格，您將承受每股$的立即稀釋，代表本次發行後我們的調整後每股淨有形價值與公開發行價格之間的差額。在現有期權或認股權證被行使或限制性股票獲准後，您可能會進一步受到稀釋。有關您在本次發行後立即會遇到的稀釋情況的更多信息，請參見標題為“稀釋”的部分。

未來可能會因未來股權或債務發行或其他發行我們普通股的情況而導致未來稀釋。

為了籌集額外資本，我們將來可能會提供額外的普通股或其他證券，包括可轉換為或可兌換成我們普通股的證券，價格可能不同於本次發行每股價格。我們可能會在任何其他發行中以低於投資人在本次發行中支付的每股價格的價格出售股票或其他證券，未來購買股票或其他證券的投資人可能擁有優於現有股東的權利。增資發行更多的我們普通股或其他可轉換成普通股的證券，可能會顯著稀釋我們的股東。

我們擁有本次發行的淨收益的廣泛自主權，可能會以您不同意的方式投資或支出淨收益，而這些方式可能不會為您的投資帶來回報。

儘管我們目前打算按照本說明書補充的「資金用途」部分所述的方式使用此次供款的淨收益，但我們的管理階層將在使用此次供款的淨收益上享有廣泛裁量權，並可能以並不改善我們的營運結果或增強我們普通股價值的方式花費這筆收益。您將無法影響我們如何使用此次供款的淨收益的決定。我們的管理階層未能有效運用這些基金可能導致財務損失，進而損害我們的業務並導致我們普通股價格下跌。在使用這些資金之前，我們可能以不帶來收益或損失價值的方式將來自此次供款的淨收益進行投資。

由於我們預計在可預見的未來不會向股東支付任何現金股息，因此，如果有的話，資本增值將是您唯一的獲利來源。

我們從未宣布或支付過現金分紅派息給我們的資本股。我們目前打算保留所有未來的收益（如果有的話），用來財務我們業務的成長和發展。因此，我們普通股票的資本增值（如果有的話）將是您未來可見的唯一收益來源，而尋求現金分紅派息的投資者不應購買我們的普通股。

關於前瞻性陳述的特別說明

本說明書補充內容、隨附說明書以及本說明書補充內容及隨附說明書所引入的信息中包含根據1933年證券法第27條和交易法第21E條（已修訂）的前瞻性陳述，涉及重大風險和不確定性。除了本說明書補充內容、隨附說明書以及本說明書補充內容及隨附說明書中所含的歷史事實陳述之外，包括有關我們的策略、未來營運、未來財務狀況、未來營業收入、預期成本、前景、計劃和管理層的目標以及預期市場增長的所有陳述均屬前瞻性陳述。"Anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would"和類似表達旨在識別前瞻性陳述，儘管並非所有前瞻性陳述均包含這些識別性詞語。

在本增補說明書、隨附的說明書和本增補說明書及隨附的說明書中所錄入的信息中，這些前瞻性陳述包括對以下事項的描述：

我們可能無法實際達成我們前瞻性陳述中所披露的計劃、意圖或期望，您不應過分依賴我們的前瞻性陳述。實際結果或事件可能與我們所作的前瞻性陳述中披露的計劃、意圖和期望有重大差異。我們在本招股說明書補充文件的警語聲明中包括了重要因素，尤其是在“風險因素”部分，以及我們於2023年12月31日結束的年度報告10-k表中，我們隨後提交的或補充的美國證券交易委員會文件，已納入本招股說明書補充文件和附帶招股說明書中，這可能導致實際結果或事件與我們所作的前瞻性陳述有重大差異。

您應該完整地閱讀本增補說明書、附屬說明書以及本增補說明書和附屬說明書中所納入的參考資料，並理解我們實際未來的結果可能與我們的預期有重大差異。我們不承擔更新任何前瞻性陳述的義務，除非法律要求，無論是基於新信息、未來事件或其他方面。

本說明書補充資料、隨附的說明書以及本說明書補充資料和隨附的說明書中所引用的資訊均包括我們從行業刊物、調查和研究以及第三方進行的研究所獲得的統計和其他行業和市場數據。本說明書補充資料、隨附的說明書和本說明書補充資料和隨附的說明書中所引用的所有市場數據涉及許多假設和限制，請勿過分重視此類數據。此外，我們未來表現及我們經營市場的未來表現的預測、假設和估計必然面臨高度不確定和風險。

法律事項S-10

我們估計，通過本次發行和銷售我們普通股股票，淨收益將約為$百萬，如果承銷商行使其購買額外股票的選擇權，則該金額將約為$百萬，以上金額在扣除我們支付的承銷折扣和佣金及預計發行費用後。

我們打算利用本次發行的淨收益作為一般企業用途，包括營業費用、運營資金和資本支出，以加速南非和冰島濃縮設施的施工。

截至2024年6月30日，我們的現金及現金等價物約為2830萬美元，在2024年7月從公開發行普通股中，扣除包括承銷折扣、佣金和發售費用後，我們收到約3230萬美元的淨收益。我們認為，這次發行所得的淨收益，加上我們現有的現金，將足以滿足未來至少12個月的資金需求。但我們可能會通過股本或債務融資計劃籌集額外的所有基金类型。我們未來的資本需求、額外資金的可用性和取得範圍，將取決於許多因素，包括這份說明書補充部分中所描述的，並在這份說明書補充部分和相關說明書中引用的“風險因素”一節中。

截至本說明書補充之日期，我們無法確定將從本次發行活動中獲得的淨收益的所有特定用途。因此，我們的管理層將對從本次發行中獲得的淨收益的時間和用途享有廣泛的裁量權。在我們上述使用本次發行的淨收益之前，我們計劃將本次發行的淨收益投資於短期、利息收入、投資級別的工具、存款證明或直接或保證的美國政府債務。

分紅政策

我們從未在普通股上宣布或支付現金分紅派息。 我們目前打算保留所有可用資金和未來收益，以支持業務的發展和擴張，我們不預期在可預見的將來支付任何現金分紅派息。 未來支付現金分紅的決定將由我們的董事會酌情決定，受適用法律約束，並取決於多個因素，包括我們的財務狀況、營運結果、資本需求、合約限制、一般業務狀況，以及我們的董事會認為相關的任何其他因素。

稀釋

如果您參與本次發行，投資我們普通股，您的所有權將立即被稀釋，具體程度取決於您在本次發行中支付的每股公開發行價格與本次發行後我們普通股每股經調整淨有形資產價值之間的差額。

我們截至2024年6月30日的歷史淨有形資產價值為770萬美元，每股普通股為0.15美元。截至2024年6月30日，我們的歷史淨有形資產價值是我們的總有形資產減去我們的總負債和非控股權益的金額。歷史淨有形資產價值每股代表我們的歷史淨有形資產價值除以截至2024年6月30日未償還的普通股股份。

扣除由我們支付的承銷折扣、佣金和估計的發行費用後，根據本次發行的普通股股票以每股$的公開發行價格，截至2024年6月30日，我們調整後的淨有形帳面價值將為$百萬，或每股$。這代表對現有股東調整後的淨有形帳面價值增加$，對參與本次發行購買我們普通股的投資者則導致調整後的淨有形帳面價值每股減少$。本次發行購買我們普通股的投資者的每股稀釋受到投資者支付每股公開發行價格後的調整後的淨有形帳面價值減去本次發行後的調整後每股淨有形帳面價值的影響。以下表格說明了這種對於參與本次發行購買我們普通股的投資者的稀釋，未考慮承銷人行使其購買額外股份選擇權的情況。

如果承銷商完全行使其購買額外股份的選擇權，調整後的淨有形帳面價值將提高至每股 $，對現有股東每股增加 $，對在本次發行中購買我們普通股的投資者每股立即稀釋 $。

以上表格基於2024年6月30日截至的52,132,833股普通股，不包括：

在期權或認股權被行使的情況下，將發行新的期權、認股權或限制性股票獎，或在上述事件或未來其他任何原因下發行額外的普通股，將對參與本次發行的投資者造成進一步稀釋。

對於我們普通股的非美國持有人，美國聯邦所得稅和遺產稅的考慮事項

以下是有關美國聯邦所得稅和遺產稅的材料討論，涉及非美國持有人擁有和處分我們普通股時的稅務考慮。在本討論中，"非美國持有人" 一詞是指我們普通股的有利擁有人（除了合夥企業或其他分配實體），並且不是聯邦所得稅目的地的人：

本論言基於美國1986年入法正美式或修改之的現行程序。我借用作為「程序」來澫，及所有現行及已採變美國金展規注釛度貼程、現行行政規宠2021年们依滿故表神和歷利決譽後有效於程序的明細貼程，而個判話袋，可能會威背性費效。任一變更或威背費效可以复诊未來的不同觀議和確。多起，沒有供府程序會无意志挖战方格中的程序費效討論之一或曝，以至於可能威背費效作。

本討論僅針對持有我們普通股的非美國持有人，該股票作為資本資產（一般而言，持有以投資為目的的財產）。本討論不涵蓋所有與個別非美國持有人的情況相關的美國聯邦所得稅和遺產稅的所有方面，也不涵蓋最低替代稅、對淨投資收入徵收的醫療保險稅，以及美國、州或非美國稅的任何方面。本討論還不考慮可能適用於非美國持有人的任何具體事實或情況，也不涵蓋適用於特定非美國持有人的特殊稅收規定，例如：

此外，此討論並未涉及合夥企業或通過合夥企業或其他用於美國聯邦所得稅目的的穿透性實體持有其普通股的合夥人或其他人士的稅務處理。將持有我們的普通股的合夥企業合夥人或其他穿透性實體應就通過合夥企業或其他穿透性實體購買、持有和處置我們的普通股的稅務後果諮詢其自己的稅務顧問，適用時。

有意投資者應就購買、持有和處置我們的普通股涉及的美國聯邦、州、地方和非美國收入以及其他稅務問題諮詢自己的稅務顧問。

分紅派息

如果我們對我們的普通股支付分紅派息，則該分紅一般將依據美國聯邦所得稅原則，從我們的當前或累積盈利中支付，該支付通常將構成分紅。 如果分紅超過我們的當前和累積盈利，則超額部分將被視為非美國持有人投資的免稅退回，最多不超出該持有人對普通股的稅基。 任何剩餘的超額部分將被視為資本利得，適用於下文“-出售普通股的利得”標題下所描述的稅務待遇。

非美國股東所獲的股息通常將受到美國聯邦所得稅的30%扣繳，或者可能根據美國與該股東所居住國家之間的適用所得稅協定而訂定的較低稅率。索取我們普通股所獲得適用所得稅協定條款的非美國股東通常應提供完整填寫的IRS Form W-8BEN或W-8BEN-E（或後續表格）並符合相關認證和其他要求。符合所得稅協定規定的非美國股東可通過及時提交適當的要求給IRS來獲得退稅或抵免任何過多扣繳的金額。

若非美國持有人將分紅視為與其在美國內進行的業務有實質聯繫，且如果適用的所得稅協定規定如此，並歸因於非美國持有人在美國內設立的永久性機構或固定基地，則通常免徵30%的扣繳稅。若非美國持有人符合適用的證明和披露要求。然而，此類美國有實質聯繫的收入將以凈利潤基礎按照與《稅法》中所定義的美國人適用的相同美國聯邦所得稅率徵稅。任何一家非美國持有人收到的有實質聯繫的美國收入，若其為公司，也可能根據美國與其居住地國家之間的適用所得稅協定，在某些情況下，受到30%的“分支利潤稅”或可能由協定所指定的更低稅率的納稅。

建議非美國持有人諮詢其自己的稅務顧問，以了解其根據適用所得稅條約的權利。

普通股份處置收益

非美國持有人一般在出售我們的普通股所認識的利得上，通常不會受到美國聯邦所得稅的稅款影響，除非：

資訊報告和備份扣繳

我們必須每年向美國國稅局和每位非美國持有人報告支付給該持有人的普通股的分紅總額和相關分紅的扣繳稅額（如有）。非美國持有人可能需要遵守特定的認證程序，以確定持有人不是美國人（根據《稅法》定義），以避免對我們的普通股分紅進行可適用稅率（目前為24％）的備用扣繳。通常，非美國持有人將遵守這些程序，如果提供適當簽署的IRS W-8BEN或W-8BEN-E表格（或其他適用的W-8表格）或以其他方式符合證明要求以確定其為非美國持有人，或另外建立豁免。按照上述“- 分紅”標題下述及的正在扣繳的美國聯邦所得稅的非美國持有人支付的分紅，通常將免於美國的備用扣繳。

對於非美國持有人通過或通過任何美國或外國經紀的美國辦事處處置我們普通股所得的情況，一般將適用資料報告和備份扣繳，除非持有人證明其為非美國持有人並符合某些其他要求，或者以其他方式確立豁免。一般來說，對於非美國持有人通過經紀的非美國辦事處在美國以外進行業務的處分所得支付，將不適用資料報告和備份扣繳。然而，就資料報告而言，透過持有大量美國擁有權或業務的非美國辦事處進行處分通常將被視為與透過經紀的美國辦事處進行處分類似。非美國持有人應諮詢其自己的稅務顧問，以了解資訊報告和備份扣繳規則對其的應用。

信息報表的復本可能根據特定條約或協議的規定提供給非美國持有人居住或註冊地的稅務機構。

備用代扣不是額外的稅項。相反，根據備用代扣規則扣除的任何金額，從向非美國持有人的付款中扣除的金額，如果有必要，可以向IRS提出適當的申請及時退還或抵免非美國持有人的美國聯邦所得稅責任。

FATCA

《代碼中稱為外國賬戶稅收合規法案（FATCA）的條款通常對我們的普通股股息及出售或處分所得施加30%的預扣稅，除非支付給外國實體，除非（i）該外國實體是“外國金融機構”，該外國實體履行某些盡職調查、報告、預扣稅和證明義務，（ii）如果該外國實體不是“外國金融機構”，則該外國實體識別其某些美國投資者，或（iii）該外國實體在FATCA下另有規定獲得豁免。

根據FATCA，通常適用於我們普通股的分紅支付。儘管FATCA還適用於我們普通股出售或其他處置所得款項的扣繳，根據美國財政部提議的法規，不需要對總收入支付的款項進行扣繳。儘管該法規尚未最終確定，但適用的扣繳機構可以在最終法規出台前依賴提議的法規。

如果在涉及我們普通股的任何支付中，根據FATCA有必要扣繳稅款，則沒有其他必須扣繳（或其他本應享有扣繳減免率）這種支付的投資者可能需要向IRS尋求退款或信用。美國與相應外國國家之間的政府間協議可能修改本部分所述要求。非美國持有人應諮詢他們自己的稅務顧問，了解FATCA對他們在我們普通股中的投資以及持有我們普通股的實體可能帶來的潛在影響。

聯邦遺產稅

我們共同持有的股票或被視為由在死亡時為非美國持有人（根據美國聯邦遺產稅目的特別定義）擁有的個人持有，將被納入該個人的美國聯邦遺產稅目的總資產，因此可能需繳納美國聯邦遺產稅，除非適用的遺產稅或其他條約另有規定。

有關美國聯邦稅務考量的前述討論僅供潛在投資者參考。不構成稅務建議。潛在投資者應就購買、持有和處置我們的普通股的美國聯邦、州、地方和非美國稅務後果，包括擬議法律變更的後果，諮詢其自己的稅務顧問。

包銷商承銷

根據本補充說明書日期的承銷協議條款和條件，下文所列承銷商已同意購買我們同意賣給承銷商的下面指示數量的股份：

承銷商有義務在本說明書補充中提供的所有普通股中買入並支付所有這些股份。但是，如果承銷商選擇購買以下描述的附加股份的選擇權，則承銷商無需購買或支付這些股份。

承銷商最初建議將普通股的部分股份直接以本招股書補充內容封面列明的發行價格向公眾發售，另一部分以不超過每股$ 的讓步價格向某些經銷商發售。在普通股的首次發行後，發售價格和其他銷售條款可能不時被承銷商修改。

我們已向承銷人授予選擇權，自本說明書補充說明日期起計30天內行使，以公開發售價格購買本說明書補充說明封面頁上列出的普通股額外股份，扣除承銷折扣和佣金。

以下表格顯示每股的公開發行價、包銷折扣和佣金、以及在扣除開支前我們獲得的款項。這些金額是根據假設包銷人行使購買額外普通股的權利，而且不論有無行使全部權利。

本公司預計支付的發行費用，不包括承銷折扣和佣金，大約是$。我們已同意就特定費用對承銷商進行補償，包括與金融行業監管局有關的任何事宜，以及本次發行的股份符合州證券法的資格，總金額最高為$100,000。

我們的普通股在納斯達克上市，交易標的為“ASPI。”

我們和所有董事和高級主管（“鎖倉方”）已同意，在某些例外情況下，在本招股說明書補充之日起90天內（“限制期”之日前）未經承銷商事先書面同意，我們和他們將不會公開進行，或者不會公開透露有意於該期結束之前。

前段描述的限制不適用於由鎖定方進行的此類轉讓或處置。

此外，上述限制不適用於某些情況，包括：

承銷商依其獨立判斷，可以隨時全部或部分釋出上述禁售協議所描述的普通股和其他證券。

為了促進普通股的發行，承銷商可能會進行穩定、維持或以其他方式影響普通股價格的交易。具體來說，承銷商可能會賣出比其在承銷協議下買入的股票份數更多的股份，從而形成空頭頭寸。如果空頭頭寸不超過承銷商按照選擇權應該購買的股份數，則所謂的空頭賣空就是有擔保的。承銷商可以通過行使選擇權或在公開市場上購買股票來結束有擔保的空頭賣空。在決定來源以結束有擔保的空頭賣空時，承銷商將考慮，除其他事項外，股份的公開市場價格與選擇權下可獲得價格之間的比較。承銷商還可能賣出超過選擇權的股份，從而形成裸空頭頭寸。承銷商必須通過在公開市場上購買股份來結束任何裸空頭頭寸。如果承銷商擔心定價後公開市場對普通股價格可能產生向下壓力，影響購買本次發行股票的投資者，則更有可能形成裸空頭頭寸。為了進一步促進這次發行，承銷商可以在公開市場上競標並購買普通股，以穩定普通股價格。這些活動可能使普通股的市場價格升高或保持在獨立市場水平之上，或防止或減緩普通股市場價格下跌。承銷商不必參與這些活動，也可以隨時終止其中任何一項。

我們和承銷商已同意相互賠償某些責任，包括證券法下的責任。

承銷商及其聯屬公司過去已為我們、我們的子公司和聯屬公司提供過各種投資銀行、商業銀行和其他金融服務，未來可能繼續提供，而這些服務已經收取過慣例費用，未來可能繼續收取。

在進行本次發行的承銷商或販售團成員之一（如有）維護的網站上，可能提供電子形式的說明書補充資料。

銷售限制

歐洲經濟區

就歐洲經濟區的每一個成員國和英國（各自為“相關國家”）而言，在當有關國家出版經相應當局批准的有關證券的計劃書之前，不得根據有關證券向公眾公開發售，除非這已根據《計劃書法》在該相關國家得到批准或在其他相關國家得到批准並通知在該相關國家的當局，一切均按照《計劃書法》的規定，該相關國家可能根據計劃書法的以下豁免條款隨時向該相關國家公眾發行證券：

倘若此等股票供應並無需我們或我們的代表根據《說明書規例》第3條發布招股說明書，或根據《說明書規例》第23條補充招股說明書。

根據本條款的目的，“向公眾提出”這個術語與相關國家的任何股票之間的表達，表示通過任何形式和方式傳達有關要約條款和擬提供的任何股份的充足信息，使投資者能夠決定購買任何股份，“招股書規定”這個術語指的是規定（EU）2017/1129（經修訂） 。

英國 

每位承保人均表示並同意：

法律問題

本次我們提供的普通股的股份有效性正在由Blank Rome LLP審核。Goodwin Procter LLP在這次發行中擔任承銷商的法律顧問。

專家

ASP同位素公司及其子公司截至2023年和2022年12月31日的合併資產負債表，以及相關的合併損益表、綜合損益表、股東權益變動表和現金流量表，已由獨立註冊的會計事務所EisnerAmper LLP進行審計，其報告已納入參考，報告包含關於存在重大疑問有關公司能否作為持續經營實體的解釋段落。這些基本報表已納入參考，依賴該會計和審計專家憑其授權給出的專業報告。

更多資訊可於以下地方找到

我們向證券交易委員會提交年度、季度和當前報告、代理人聲明和其他資訊。我們的SEC提交公開在互聯網上證券交易委員會的網站www.sec.gov 可用。我們向證券交易委員會提交的某些信息的副本也可以在我們的網站www.aspisotopes.com上獲得。證券交易委員會的網站和我們的網站並不屬於本補充說明書的一部分，也不被納入本補充說明書的參考資料。

本說明書補充資料是我們向SEC提交的登記申明書的一部分。 該登記申明書包含比這份說明書補充資料和隨附的說明書更多關於我們和證券的資訊，包括某些展示和附表。 您可以從SEC的網站和我們的網站獲取登記聲明書的副本。

透過引用納入特定資訊

證交所允許我們將已提交給證交所的大部分信息納入本增補說明書和隨附的說明書，這意味著我們可以通過讓您參考那些已公開的文件向您披露重要信息。我們納入本增補說明書和隨附的說明書的信息被認為是本增補說明書和隨附的說明書的一部分。由於我們正在將未來提交給證交所的文件納入參考，本增補說明書和隨附的說明書將不斷更新，而未來的提交可能修改或取代包含在本增補說明書和隨附的說明書中的部分信息。這意味著您必須審查我們納入參考以判斷本增補說明書、隨附的說明書或以前納入參考的任何文件中的任何聲明是否已經被修改或取代。

本招股說明書和隨附的招股說明書通過引用以下列出的文件（在每種情況下，均不包括向美國證監會提交的文件或其中未被視爲向美國證監會提交的文件的部分），直至證券註冊聲明的發行終止或完成爲止：

我們還通過引用將我們可能在完成或終止發行前根據《交易所法》第13(a)、13(c)、14或15(d)條向證券交易委員會提交的其他文件納入本招股說明書補充資料和隨附的招股說明書中，但排除未與證券交易委員會提交的任何信息。 任何包含在先前已提交文件中的聲明被視爲根據本招股說明書補充資料和隨附的招股說明書的目的進行修改或取代，以便在本招股說明書補充資料和隨附的招股說明書中包含的聲明，或在隨後提交的文件中也被納入本招股說明書補充資料和隨附的招股說明書的聲明，修改或取代該聲明。

我們將免費向收到本招股說明書補充和隨附招股說明書的每位個人提供任何被引用的信息的副本。如需此類文件，請致函或口頭要求至以下地址：

asp isotopes公司。

華盛頓特區賓夕法尼亞大道601號

南樓，900套房

華盛頓特區20004

(202) 756-2245

注意：公司秘書

您還可以免費訪問本招股說明書補充中通過參考而納入的文件，可通過SEC網站www.sec.gov或我們的網站www.aspisotopes.com免費獲取。SEC網站或我們的網站上包含的信息不屬於也不被納入本招股說明書補充，您不應將SEC網站或我們的網站上的信息視爲本招股說明書補充的一部分。

根據424（b）（5）規則提交

文件編號333-279857

招股說明書

$50,000,000

普通股

優先股

債務證券。

權證

單位

我們可能不時提供並出售本招股說明書中描述的任何證券，可以單獨或與其他證券組合，以總計高達5000萬美元的標售價進行一次或多次發行。

本招股說明書提供了我們可能提供的證券的一般描述。我們將在本招股說明書的一個或多個附錄中提供證券的具體條款。招股說明書附錄還將描述這些證券將以特定方式進行的具體情況。我們還可能授權一個或多個自由撰寫招股說明書與這些發行相關的提供給您。招股說明書附錄和任何相關的自由撰寫招股說明書可能添加、更新或更改本招股說明書中包含的信息。在您投資我們的任何證券之前，請仔細閱讀本招股說明書、適用的招股說明書附錄、任何相關的自由撰寫招股說明書以及參考的文件。本招股說明書不能用於出售任何證券，除非附有適用的招股說明書附錄。

我們的普通股在納斯達克資本市場（「納斯達克」）上市，股票代碼爲「ASPI」。截至2024年5月30日，我們的普通股最後報告交易價格爲每股5.43美元。如適用，相關的招股說明書將包含有關在納斯達克或其他證券市場或交易所上市的任何其他證券，如果有的話。

投資我們的證券涉及高風險。請參閱本招股說明書第7頁上的「風險因素」以及任何補充材料，了解在與我們的證券的投資有關的應考慮的信息的討論。風險因素根據本招股說明書第7頁及納入本招股說明書的文檔，經適用的招股說明書補充更新，任何相關的自由撰寫招股說明書以及我們未來向證券交易委員會提交併納入本招股說明書的文件，詳細討論我們建議您在決定購買我們的證券之前仔細考慮的因素。

我們可能直接向投資者出售這些證券，也可能通過不時指定的代理商或承銷商進行出售。有關銷售方法的更多信息，請參閱題爲“"分銷計劃”的部分。如果有任何承銷商參與向交付本招股說明書的證券出售，這些承銷商的名稱以及任何適用的佣金或折扣將在招股說明書的補充中列出。此類證券的公開價格和我們預計從此次銷售中收到的淨收益也將在招股說明書的補充中列出。

證券交易委員會或任何州證券委員會尚未批准或否認這些證券或確定本招股說明書是否真實或完整。任何相反的陳述均構成犯罪。

本招股說明書日期爲2024年6月12日

目錄

關於本招股說明書

本招股說明書是我們根據1933年修正案股票法案向證券交易委員會（「SEC」）註冊的一部分，採用「貨架」註冊程序。根據這一貨架註冊程序，我們可能不時地以高達5000萬美元的總髮行價，通過本招股說明書中描述的各種證券的任何組合，進行一項或多項發行和銷售。

本招股說明不得用於提供和銷售證券，除非附有適用的招股說明。

本招股說明書提供了我們可能發行的證券的一般描述。每次我們根據本招股說明書賣出證券時，我們將提供一個包含有關該發行條款的具體信息的招股說明書補充。我們還可能授權提供一個或多個自由書面招股說明書，其中可能包含與特定發行有關的重要信息。招股說明書補充及任何相關的自由書面招股說明書還可能添加、更新或更改本招股說明書中或我們已通過引用納入本招股說明書的任何文件中包含的信息。在本招股說明書、任何適用的招股說明書、任何相關的自由書面招股說明書或任何已通過引用納入本招股說明書的文件中的任何聲明之間存在衝突的程度上，具有較晚日期的文件中的聲明修改或取代先前的聲明。

本招股說明書或任何招股說明書補充資料中出現的信息僅截至各自日期有效，我們引用的任何信息僅截至被引用文件的日期有效，不論本招股說明書、適用的招股說明書補充資料或任何相關的自由書寫招股說明書何時交付，或任何證券的銷售時間。我們的業務、財務狀況、經營業績和前景自那些日期以來可能發生了重大變化。

您只能依賴本招股說明書中包含或引用的信息，或任何適用的招股說明書附錄中包含的信息，或者根據特定發行活動授權使用的任何自由寫作招股說明書中包含的信息。我們未授權任何人向您提供不同或額外的信息。

本招股說明書、任何招股補充文件或任何相關的自由書面招股說明，並非構成賣出或買入本招股說明書或適用的招股補充文件中描述的證券以外的任何證券的要約或要約買入，或在任何情況下或任何法域中對這些證券進行賣出或買入的要約或邀約均屬違法。

根據SEC規則和法規的許可，本招股說明書作爲一部分的註冊聲明包括了本招股說明書中未包含的附加信息。本招股說明書還包括了對所述文件中某些條款的摘要，但所有摘要均在其整體上通過參照實際文件而受到限制。您可以閱讀註冊聲明以及我們向SEC提交的其他報告，並且您可以在SEC的網站上或本招股說明書中所述部分「」中描述的辦公室獲取本招股說明書中總結的實際文件副本（如在提交給SEC時）。您可以在哪裏找到更多信息.”

我們在作爲招股說明書的一部分而被作爲展示文件提交的協議中所作的陳述、擔保和契約僅爲該等協議的各方（包括在某些情況下爲了在該等協議各方之間分配風險）的利益而作，並不應被視爲對您的陳述、擔保或契約。而且，該等陳述、擔保或契約僅在其作出時的日期準確。因此，不應依賴於這些陳述、擔保和契約來準確代表我們事務的最新狀況。

風險因素

投資我們的證券涉及高風險。適用於我們證券每一項發行的招股說明書將包含與投資asp isotopes公司相關的風險討論。在做出投資我們證券的決定之前，您應仔細考慮招股說明書中「」標題下討論的具體因素，以及招股說明書中包含或引用的所有其他信息，或包含或引用在本招股說明書中的信息。您還應考慮我們最近一份10-k表格年度報告中含有的「」標題下討論的風險、不確定性和假設，可能會由我們隨後提交給SEC的季度10-Q報告或我們已提交給SEC的8-k現行報告進行更新，所有這些已被引用在此，未來我們向SEC提交的報告可能會進行修訂、補充或替代。我們描述的風險和不確定性並不是我們所面臨的唯一挑戰。我們目前尚不知曉的其他風險和不確定性，或我們目前認爲不重要的風險和不確定性也可能影響我們的運營。這些風險發生可能會導致您在發行的證券中失去全部或部分投資。風險因素在我們的證券上投資涉及高風險。適用於每一次證券發行的招股說明書將包含與對asp isotopes 公司投資相關的風險討論。在做出有關投資我們證券的決策之前，您應仔細考慮招股說明書中「」標題下討論的特定因素，以及招股說明書中包含或引用的所有其他信息，或出現在本招股說明書中的信息。您還應考慮到我們最新的10-k表格年度報告中包含的「」標題下討論的風險、不確定性和假設，可能會被我們隨後提交的季度10-Q報告或我們已提交給SEC的當前8-k報告進行更新，所有這些信息均已被引用在此處，並且可能會在今後提交的報告中進行修訂、補充或更新。我們描述的風險和不確定性並非我們所面臨的唯一風險。我們目前未知或目前認爲不重要的其他風險和不確定性，也可能會影響我們的運營。任何這些風險的發生可能導致您在所提供的證券中失去全部或部分投資。風險因素風險和不確定性的描繪並不是我們所面臨的唯一挑戰。目前我們不知道的其他風險和不確定性，或我們目前認爲不重要的風險和不確定性，可能會對我們的運營產生影響。任何這些風險的發生可能導致您在提供的證券中失去全部或部分投資。

有關前瞻性聲明之特別說明

本招股說明書，包括在此引用的文件，包含，任何招股說明書補充可能包含前瞻性聲明。這些聲明基於管理層關於未來事件、條件和成果的信念、期望和假設，以及當前對管理層可獲得的信息。本招股說明書中包含的所有聲明，包括在此引用的文件，以及任何招股說明書中，除歷史事實聲明外，均爲前瞻性聲明，包括但不限於關於我們能否以具有成本效益的方式完成、啓用和成功運作同位素富集廠的能力；我們能否滿足使用ASP技術或量子富集工藝可能生產的同位素相關監管要求的能力；我們能否獲得同位素生產和分配的監管批准的能力；我們能否滿足資本需求並獲得資金用於運營和未來增長的能力；以及關於我們的業務戰略、資本使用、經營成果和財務狀況，以及未來業務計劃和目標的聲明。在某些情況下，您可以通過詞語「可能」、「將」、「可能」、「應當」、「期待」、「打算」、「計劃」、「預計」、「相信」、「估計」、「預測」、「項目」、「潛在」、「持續」、「進行中」或這些詞語的否定形式，以及意圖識別關於未來的聲明，儘管並非所有前瞻性聲明都包含這些詞語。包含這些前瞻性聲明討論可在其他地方找到，其中包括從我們最近的年度10-K表格中引用的「業務」、「風險因素」和「管理層對財務狀況和經營成果的討論」部分，以及我們的10-Q季度報告，以及與之有關的任何修訂，已向美國證券交易委員會提交。

由於前瞻性聲明固有地受到風險和不確定性的影響，其中一些是無法預測或量化的，因此您不應將這些前瞻性聲明視爲對未來事件的預測。我們前瞻性聲明中所反映的事件和情況可能無法實現或發生，實際結果可能會與前瞻性聲明中所預測的產生重大差異。

本招股說明書，包括所引入的文件，還包含由獨立方和我們提供的有關市場規模、增長以及我們所在行業其他數據的估計和其他統計數據。這些數據涉及多種假設和限制，我們提醒您不要過分重視這些估計。此外，關於我們未來績效以及我們所處市場未來績效的預測、假設和估計必然受到高度不確定性和風險的影響。

除非法律要求，我們不承擔更新這些前瞻性聲明的義務，也不會公開修訂任何前瞻性聲明以反映本招股說明書日期之後發生的事件或發展，即使將來有新信息可獲得。所有前瞻性聲明均受此警告性聲明的完整約束。

使用資金

我們將保留對此處提供的證券銷售所得款項的廣泛自主裁量權。除非在我們授權向您提供的任何招股書補充說明書或任何相關的自由書面招股說明書中另有說明，我們目前打算將此處提供的證券銷售所得款項用於營運資金和一般企業用途，包括資本支出、償還債務、研發、銷售和市場營銷以及一般行政開支。我們也可能將部分證券銷售所得款項用於收購或投資與我們業務互補的企業、產品和技術，儘管在本招股書日期之前，我們並沒有針對任何此類收購或投資的當前計劃、承諾或協議。在運用所得款項之前，我們可能將所得款項投資於短期、投資級、利息-bearing證券、存款證書或美國政府的直接或擔保債務。

我們將在適用的招股說明書補充或自由寫作招股說明書中規定，闡明我們計劃如何利用根據招股說明書補充或自由寫作招股說明書出售的證券所獲得的淨收益。

股本結構描述

下面對我們股本的描述是一個摘要，不代表完整內容。它是根據我們的公司證書和修正及重申的公司章程，或稱「章程」，進行限定的。這一描述還總結了特拉華州法律的相關條款。我們的公司證書和章程作爲展示文件提交給註冊聲明，本招股說明書是其中的一部分。我們鼓勵您閱讀我們的公司證書、章程和特拉華州法律的適用條款以獲取更多信息。

總體來說

截至本招股說明書的日期，我們的公司章程授權發行5億股普通股，每股面值爲$0.01，和1000萬股優先股，每股面值爲$0.01，其中所有優先股都未指定。截至2024年5月30日，已發行和流通的普通股爲51,762,833股，未發行和流通的優先股爲0股。

Common Stock

The holders of our common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. The holders of our common stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our board of directors out of funds legally available, subject to preferences that may be applicable to preferred stock, if any, then outstanding. In the event of a liquidation, dissolution or winding up of our company, the holders of common stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. Our common stock has no preemptive or conversion rights or other subscription rights or redemption or sinking fund provisions.

Our common stock is traded on Nasdaq under the symbol “ASPI.”

The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC (formerly, American Stock Transfer & Trust Company, LLC). The transfer agent’s address is 6201 15th Avenue, Brooklyn, New York 11219.

Preferred Stock

Our Certificate of Incorporation authorizes our board of directors to establish one or more series of preferred stock. Unless otherwise required by law or any stock exchange, the authorized shares of preferred stock will be available for issuance without further action by the holders of our common stock. Our board of directors will be able to determine, with respect to any series of preferred stock, the powers (including voting powers), preferences and relative, participating, optional, conversion or other special rights, and the qualifications, limitations, or restrictions thereof. No shares of preferred stock have been issued or are outstanding as of the date of the filing of this registration statement. If we sell any series of preferred stock under this prospectus, we will file a certificate of designation relating to that series, which will be incorporated by reference into the registration statement of which this prospectus forms a part. The prospectus supplement will describe:

Anti-Takeover Matters in our Governing Documents and Under Delaware Law

Our Certificate of Incorporation and our Bylaws contain, and the DGCL contains, provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control, and enhance the ability of our board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an antitakeover effect and may delay, deter, or prevent a merger or acquisition by means of a tender offer, a proxy contest, or other takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by stockholders.

Authorized But Unissued Capital Stock

The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger, or otherwise.

Classified Board of Directors

Our Certificate of Incorporation provides that our board of directors be divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. Directors may only be removed from our board of directors for cause by the affirmative vote of at least 662∕3% of the voting power of all of our then-outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class. In addition, our Certificate of Incorporation provides that, subject to the rights granted to one or more series of preferred stock then outstanding, any newly created directorship on the board of directors that results from an increase in the number of directors and any vacancies on our board of directors will be filled only by the affirmative vote of a majority of the remaining directors, even if less than a quorum, or by a sole remaining director. A director chosen to fill a position resulting from an increase in the number of directors will hold office until the next election of the director’s class and until the director’s successor is duly elected and qualified, or until the director’s earlier death, resignation or removal. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of us or changes in our management.

Delaware Anti-Takeover Law

We are subject to Section 203 of the DGCL, which is an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date that the person became an interested stockholder, unless the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Generally, a business combination includes a merger, asset or stock sale, or another transaction resulting in a financial benefit to the interested stockholder. Generally, an interested stockholder is a person who, together with affiliates and associates, owns 15% or more of the corporation’s outstanding voting stock or is the corporation’s affiliate or associate and was the owner of 15% or more of the corporation’s outstanding voting stock at any time within the three-year period immediately before the date of determination. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our board, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

No Cumulative Voting

Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. Our Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our stock entitled to vote generally in the election of directors are able to elect all of our directors.

Special Stockholder Meetings

Our Certificate of Incorporation provides that special meetings of our stockholders may be called at any time only by or at the direction of the board of directors, the chair of the board of directors or our Chief Executive Officer. Our Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management.

Director Nominations and Stockholder Proposals

Our Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder’s notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. Our Bylaws also specify requirements as to the form and content of a stockholder’s notice. Our Bylaws allow the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to influence or obtain control.

Stockholder Action by Written Consent

Pursuant to Section 228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice, and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless the certificate of incorporation provides otherwise. Our Certificate of Incorporation precludes stockholder action by written consent.

Amendment of Certificate of Incorporation or Bylaws

The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or bylaws, unless a corporation’s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our Bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 662∕3% of the votes which all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 662∕3% of the votes which all our stockholders would be entitled to cast in any election of directors will be required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our Certificate of Incorporation described above.

The foregoing provisions of our Certificate of Incorporation and our Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares of common stock that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management or delaying or preventing a transaction that might benefit you or other minority stockholders.

Exclusive Forum

Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware be the sole and exclusive forum for: (1) any derivative action or proceeding brought on behalf of our company, (2) any action asserting a claim of breach of fiduciary duty owed by any director, officer, agent, or other employee or stockholder of our company to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting a claim governed by the internal affairs doctrine, in each case subject to such Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. It will further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolutions of any complaint asserting a cause of action arising under the Securities Act. The exclusive forum clauses described above shall not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in such action. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our Certificate of Incorporation.

Limitations of Liability and Indemnification

The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties, subject to certain exceptions. Our Certificate of Incorporation includes a provision that eliminates the personal liability of directors for monetary damages to the corporation or its stockholders for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. The effect of these provisions is to eliminate the rights of us and our stockholders, through stockholders’ derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation does not apply to any breaches of the director’s duty of loyalty, any acts or omissions not in good faith or that involve intentional misconduct or knowing violation of law, any authorization of dividends or stock redemptions or repurchases paid or made in violation of the DGCL, or for any transaction from which the director derived an improper personal benefit.

Our Bylaws generally provide that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We also are expressly authorized to carry directors’ and officers’ liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.

The limitation of liability, indemnification and advancement provisions in our Certificate of Incorporation and our Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought.

We have entered into indemnification agreements with each of our directors and executive officers, under which we have agreed to indemnify our directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of our company, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of our company. The indemnification agreements also set forth certain procedures, presumptions and remedies that will apply in the event of a claim for indemnification thereunder.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC such indemnification is against public policy and is therefore unenforceable.

DESCRIPTION OF DEBT SECURITIES

The following description summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities we may offer under this prospectus, the applicable prospectus supplement or free writing prospectus will describe the specific terms of any debt securities offered through that prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement or free writing prospectus may differ from the terms we describe below. Unless the context requires otherwise, whenever we refer to the “indentures,” we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.

We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the subordinated indenture that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this prospectus forms a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement, of which this prospectus forms a part, or will be incorporated by reference from reports that we file with the SEC.

The indentures will be qualified under the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”). We use the term “trustee” to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.

The following summary of material provisions of the senior debt securities, the subordinated debt securities and the indentures is subject to, and qualified in their entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplement and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete applicable indenture that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.

General

We will describe in the applicable prospectus supplement or free writing prospectus the terms of the series of debt securities being offered, including as applicable:

Conversion or Exchange Rights

We will set forth in the applicable prospectus supplement or free writing prospectus the terms on which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third-party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party) that the holders of the series of debt securities receive would be subject to adjustment.

Consolidation, Merger or Sale

Unless we provide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate and must be a corporation organized and validly existing under the laws of any U.S. domestic jurisdiction. If the debt securities are convertible into or exchangeable for other securities of ours or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale.

Events of Default under the Indenture

Unless we provide otherwise in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue:

We will describe in each applicable prospectus supplement or free writing prospectus any additional events of default relating to the relevant series of debt securities.

If an event of default with respect to debt securities of any series occurs and is continuing, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal due and payable immediately.

The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.

Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. Subject to the terms of the indentures, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that:

These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement or free writing prospectus.

We expect to periodically file statements with the trustee regarding our compliance with specified covenants in the indentures.

Modification of Indenture; Waiver

Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may enter into one or more supplemental indentures, without the consent of any holders, with respect to the following specific matters:

In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or as otherwise provided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:

Discharge

Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, we can elect to be discharged from our obligations with respect to one or more series of debt securities.

In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium and interest on, the debt securities of the series on the dates payments are due. This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that all conditions precedent provided for in the indenture relating to the discharge have been complied with.

Form, Exchange and Transfer

We plan to issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement or free writing prospectus, in denominations of $1,000 and any integral multiple thereof. We may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depository named by us and identified in a prospectus supplement or free writing prospectus with respect to that series.

At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement or free writing prospectus, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.

Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement or free writing prospectus, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.

We will name in the applicable prospectus supplement or free writing prospectus the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.

If we elect to redeem the debt securities of any series, we will not be required to:

Information Concerning the Trustee

The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.

Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.

Payment and Paying Agents

Unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.

We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement or free writing prospectus, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement or free writing prospectus any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.

All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.

Governing Law

We expect the indentures and the debt securities to be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.

Ranking of Debt Securities

The subordinated debt securities will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement or free writing prospectus. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.

The senior debt securities will rank equally in right of payment to any of our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.

Existing Long-Term Debt

On March 7, 2024, Quantum Leap Energy LLC, or “QLE,” our wholly owned subsidiary, issued convertible notes payable, or “Convertible Notes,” in the aggregate principal amount of $21,063,748 and received aggregate gross proceeds of $20,550,000.  The Convertible Notes are payable on demand on March 7, 2029 and bear an annual interest rate of 6% for the first year and 8% thereafter. Upon a qualified financing event, the Convertible Notes convert into the shares to be issued in that qualified financing event at a price per share equal to 80% of the share price issued subject to a valuation cap. Upon a qualified transaction, the noteholders may elect to receive either 1.5x the principal and accrued interest balance in cash or convert into common shares. The Convertible Notes are general unsecured obligations of QLE.  We are not a guarantor of the Convertible Notes. The Convertible Notes are subordinate in right of payment to all current and future indebtedness of QLE for borrowed money to banks, commercial finance lenders or other institutions regularly engaged in the business of lending money (whether or not such indebtedness is secured).

DESCRIPTION OF WARRANTS

The following description summarizes the material terms and provisions of the warrants that we may offer under this prospectus. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement or free writing prospectus, which may specify different or additional terms. Specific warrant agreements and warrant certificates related to warrants offered under this prospectus and any applicable prospectus supplement or free writing prospectus will contain additional important terms and provisions and will be incorporated by reference into the registration statement, of which this prospectus forms a part, from reports that we file with the SEC. 

General

We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. We plan to evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement. We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants.

We will describe in the applicable prospectus supplement the terms of the series of warrants, including as applicable:

DESCRIPTION OF UNITS

The following description summarizes the material terms and provisions of the units that we may offer under this prospectus. We may issue units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may issue units in such amounts and in as many distinct series as we deem appropriate under one or more unit agreements to be entered into between us and a bank or other financial institution, as a unit agent. The specific terms of any series of units offered will be described in the applicable prospectus supplement or free writing prospectus, and such terms may differ from the general description presented below. If we issue units, forms of unit agreements and unit certificates relating to such units will be incorporated by reference into this registration statement, of which this prospectus forms a part, from reports that we file with the SEC.

General

Each unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement, under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.

The applicable prospectus supplement may describe:

The provisions described in this section, as well as those described under “Description of Capital Stock,” “Description of Debt Securities” and “Description of Warrants” will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements.

PLAN OF DISTRIBUTION

We may sell these securities directly to one or more investors. We may also sell these securities through agents designated from time to time or to or through underwriters or dealers. We may sell these securities through “at the market” offerings, within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise. The applicable prospectus supplement and any related free writing prospectus will describe the terms of the offering of the securities, including, to the extent applicable:

We may distribute the securities from time to time in one or more transactions at:

Agents and Underwriters

We may designate agents who agree to use their reasonable efforts to solicit purchases of our securities for the period of their appointment or to sell our securities on a continuing basis. We will name any agent involved in the offering and sale of securities and we will describe any fees or commissions we will pay the agent in the applicable prospectus supplement.

If we use underwriters for a sale of securities, the underwriters will acquire the securities for their own account. The underwriters may resell the securities in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. Subject to certain conditions, the underwriters will be obligated to purchase all the securities of the series offered if they purchase any of the securities of that series. We may change from time to time any public offering price and any discounts or concessions the underwriters allow or reallow or pay to dealers. We may use underwriters with whom we have a material relationship. We will name any underwriter involved in the offering and sale of securities, describe any discount or other compensation and describe the nature of any material relationship in any applicable prospectus supplement. Only underwriters we name in the prospectus supplement will be underwriters of the securities offered by that prospectus supplement.

Underwriters, dealers and agents that participate in the distribution of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the Securities Act. We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will describe their compensation.

We may have agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities related to offerings under this prospectus, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Underwriters, dealers and agents may engage in transactions with or perform services for us in the ordinary course of their businesses.

Trading Markets and Listing of Securities

Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is currently listed on the Nasdaq Stock Market. We may elect to list or qualify for trading any other class or series of securities on any securities exchange or other market, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.

At-the-Market Offerings

To the extent that we make sales through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the terms of a sales agency financing agreement or other at-the-market offering arrangement between us and the underwriters or agents. If we engage in at-the-market sales pursuant to any such agreement, we will issue and sell our securities through one or more underwriters or agents, which may act on an agency basis or a principal basis. During the term of any such agreement, we may sell securities on a daily basis in exchange transactions or otherwise as we agree with the underwriters or agents. Any such agreement will provide that any securities sold will be sold at prices related to the then prevailing market prices for our securities. Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time. Pursuant to the terms of the agreement, we may agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase blocks of our common stock or other securities. The terms of any such agreement will be set forth in more detail in the applicable prospectus supplement.

Stabilization Activities

Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of these activities at any time.

Passive Market Making

Any underwriter who is a qualified market maker on the Nasdaq Stock Market may engage in passive market making transactions in securities listed on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. A passive market maker must comply with applicable volume and price limitations and must be identified as a passive market maker. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security. If all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded.

LEGAL MATTERS

Unless otherwise indicated in the applicable prospectus supplement, the validity of any common stock, preferred stock, debt securities, warrants or units offered under this prospectus and any supplement hereto will be passed upon for us by Blank Rome LLP, Dallas, Texas.

EXPERTS

The consolidated balance sheets of ASP Isotopes Inc. and Subsidiaries as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated by reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern. Such financial statements have been incorporated by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing.

INFORMATION INCORPORATED BY REFERENCE

SEC rules permit us to incorporate information by reference into this prospectus and any applicable prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus and any applicable prospectus supplement, except for information superseded by information contained in this prospectus or the applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus and any applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with the SEC (other than information in such documents that is deemed to be furnished and not filed). These documents contain important information about us and our business and financial condition.

All documents that we file (other than information in such documents that is deemed to be furnished and not filed), pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial filing of the registration statement, of which this prospectus forms a part, and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file ((other than information in such documents that is deemed to be furnished and not filed) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents.

本說明書中包含的任何聲明，或納入本說明書或適用的說明書附件並被視爲納入其中的文件中的任何聲明，應被視爲已經就本說明書及該適用的說明書附件的目的進行了修改或取代，至這樣的適用的說明書附件中包含的聲明，或任何其他隨後提交的文件中包含的聲明，該文件也被視爲納入本說明書及該適用的說明書附件，修改或取代了這樣更早的聲明。經修改或取代的聲明不得被視爲（除非經過修改或取代）構成本說明書或該適用的說明書附件的一部分。

已通過引用納入的文件可免費向我們獲取，所有板塊均可獲得，不包括所有附錄。

有意投資者可以通過書面或電話向我們的行政辦公室請求免費獲取併入本招股說明書和適用招股說明書的參考文件。

asp isotopes公司。

華盛頓特區賓夕法尼亞大道1101號，300套房間

華盛頓特區20004

(202) 756-2245

注意：公司秘書

                您也可以免費在SEC網站上訪問這些文件。 www.sec.gov 或者在我們的網站www.aspisotopes.com上。在SEC的網站上或者通過SEC的網站可以訪問的信息，或者在我們的網站上可以訪問的信息，均不構成本招股說明的一部分，也不被作爲本招股說明的引用，您不應將我們網站上的信息視爲本招股說明的一部分。

在哪裏尋找更多信息

根據證監會規定，該招股說明書省略了包含在註冊聲明中的某些信息，而本招股說明書是其中的一部分，以及其附件。由於本招股說明書可能沒有包含您認爲重要的所有信息，我們建議您查看這些文件的全部內容。如果我們已經將某份合同、協議或其他文件作爲註冊聲明的附件提交，而本招股說明書是其中的一部分，請閱讀附件以更全面地了解涉及的文件或事項。本招股說明書中的每一項聲明，包括上述引用的陳述，有關合同、協議或其他文件的聲明都應以參考實際文件而整體合格。

我們受《交易所法》的信息披露要求約束，根據這些要求，我們提交年度、季度和最新報告、代理聲明、信息聲明以及其他信息給SEC。您可以在SEC的網站或我們的網站上閱讀和複製我們提交給SEC的任何材料。 www.sec.gov 或者在我們的網站 www.aspisotopes.com上查看。在SEC的網站或我們的網站上包含或可以通過的信息不是本招股說明書的組成部分，也不被納入參考，您不應將我們網站上的信息視爲本招股說明書的一部分。

股份

普通股

Canaccord Genuity